Komori
Share Issuance and Disposal5187CREATE MEDIC CO.,LTD.Electrical Equipment and Precision Instruments

Notice of Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation for Directors

Payment for the disposal of 4,526 treasury shares as restricted stock compensation for 3 directors, as resolved on 27 March 2026, has been completed.

Worth reading
30Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
4526
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Disposal of Treasury Shares as Restricted Stock Compensation

Who receives how much4,526Shares

4,526 shares of the Company's common stock (treasury shares)

3 directors of the Company: 4,526 shares (excluding directors who are Audit and Supervisory Committee members and outside directors)

The lower thin line represents the existing number of shares to which these shares will be added.

¥1,134 per share
Total issue value

¥5,132,484

Categories and Number of Persons Covered
3 directors of the Company (excluding directors who are Audit and Supervisory Committee members and outside directors): 4,526 shares
Payment date
24 April 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalDisposal of Treasury Shares as Restricted Stock Compensation
Number of shares to be issued or disposed of4,526 shares of the Company's common stock (treasury shares)
Issue price and disposal price¥1,134 per share
Total issue value¥5,132,484
Payment date24 April 2026
Intended allottee3 directors of the Company: 4,526 shares (excluding directors who are Audit and Supervisory Committee members and outside directors)
Categories and Number of Persons Covered3 directors of the Company (excluding directors who are Audit and Supervisory Committee members and outside directors): 4,526 shares
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The payment procedures for the disposal of treasury shares as restricted stock compensation, as resolved at the meeting of the Board of Directors held on 27 March 2026, have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation for Directors | CREATE MEDIC CO.,LTD. (5187) timely disclosure | Komori